Who we areWe are an interdisciplinary team leading a transformative approach to drug R&D based on the modeling of complex biological systems
#drugR&D #insilicomedicine #clinicalresearchmethodology #systemsbiology #machinelearning
Hervé BRAILLY, PhD
Chairman of the Supervisory Board and co-founder of Innate Pharma
Innate Pharma is a biopharmaceutical company discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases. The Company has 4 clinical-stage programs, including 3 checkpoint inhibitors developed in the booming field of immuno-oncology. Its innovative approach has translated into major alliances with leaders in the biopharmaceutical industry such as Novo Nordisk A/S, Bristol-Myers Squibb and AstraZeneca. With this latter partner, Hervé has closed the most important deal ever signed by a French biotech in this area: a co-development and commercialization agreement including cash payments of up to US $1.275 billion as well as double digit royalties on sales.
Hervé BRAILLY was previously a researcher at Immunotech SA, a biotechnology start up acquired in 1995 by Beckman-Coulter (1986-1994), and then in charge of marketing, business development and R&D, as well as the business activities in China (1994-1998). Beginning in 1998, Hervé was the director of a business unit of the company with 65 employees, with annual sales of 30 million U.S. dollars.
Hervé BRAILLY is also treasurer of BioCluster Eurobiomed which brings together companies in life sciences and technologies in the PACA region, and is a member of the Board of Directors of INSERM Transfert and of France Biotech.
Hervé is a graduate of the Ecole des Mines de Paris (1983) and a Doctor of Immunology, with a specialization in immuno-pharmacology.